MeiraGTx Holdings
MGTX
10.82
+0.22
+2.08%
MeiraGTx Holdings
US · MGTX
#3220 by market cap
Listed 2018
10.82
+0.22
+2.08%
Live - 5344 symbols - heartbeat 203s ago
· 2026-10-08 08:05
Pre-market
11.00
+1.71%
After-hours
10.82
0.00%
- Market cap
- 1.04B
- P/E (TTM)i
- 12.44
- P/Bi
- 4.82
- EPSi
- -1.42
- Div yieldi
- 0.00%
- 52W posi
- 48%
Reader sentiment
Are you bullish or bearish on MGTX?
Anonymous reader poll. Unscientific, not investment advice.
About MeiraGTx Holdings
MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
- Founded
- 2018
- CEO
- Dr. Alexandria Forbes, PhD
- Employees
- 403
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- meiragtx.com
Company profile
- Exchange
- US
- Symbol
- MGTX
- Market-cap rank
- #3220
- Listing date
- 2018-06-08
- Market cap
- 1.04B
- Float cap
- 581.53M
- Shares out
- 96.04M
- Float shares
- 53.75M
Sectors & themes
Biotechnology
Quote time 2026-10-08 08:05:28 · For reference only, not investment advice and not tailored to your situation.